alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. - Wikidata - awgldk - TriplyDB

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.

http://www.wikidata.org/entity/Q37289632

about

Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.Influencing the decline of lung function in COPD: use of pharmacotherapy.A review of augmentation therapy for alpha-1 antitrypsin deficiency.Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes.Quantitation of circulating wild-type alpha-1-antitrypsin in heterozygous carriers of the S and Z deficiency alleles Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options?Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.The role of proteases, endoplasmic reticulum stress and SERPINA1 heterozygosity in lung disease and α-1 anti-trypsin deficiency.Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent.The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.Risk of Lung Disease in PI MZ Heterozygotes. Current Status and Future Research Directions.Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency.A 54 -year-old man with cough and dyspnea.The Challenges of Precision Medicine in COPD.Diagnosing alpha-1 antitrypsin deficiency: the first step in precision medicine.Measuring and Interpreting Serum AAT Concentration.Alpha-1 Antitrypsin PiMZ Genotype Is Associated with Chronic Obstructive Pulmonary Disease in Two Racial Groups

P2860

Q33706037-1A57D069-ACC9-4A3E-94A6-E930DC08582A Q33966001-E66CFEA1-3F13-4DC7-BD53-28735AF333ED Q34268108-96ABBC97-179D-4378-9E44-42259FAAE59A Q35063726-46BE3F30-2DF2-4CBF-8E0B-31DE45D4C1BD Q35937953-6D49102A-BD9D-4D82-B942-2081972DC70F Q37303247-3A508441-506C-44E7-A687-47385AA03E18 Q37614554-8C9E7AED-9307-46AE-A06C-1A0A61BA9E60 Q37774788-AAC3C860-9F68-4825-9915-2AC6A14A9D95 Q37894093-8A643323-3514-4F57-8FFB-CE78015092AA Q37986292-A74481BD-D8AE-4247-86E4-A540BE648F19 Q38604630-B5252893-2A2D-4EEB-B625-401F9B311D14 Q38827548-0AC4E8CF-5875-4610-8DF8-648C879D63B9 Q38988633-740BF37B-CB19-4DBF-A77E-A5D0C16C30A9 Q41991497-B5F5AAEC-57C8-41AA-8EEB-2254BEEADFD1 Q47962475-EBF6D171-232B-46E7-9C2B-5878F5FF240B Q49961017-5950427C-8FBE-411C-A6F9-CA18B089521E Q53137782-CD5B2B2A-A416-479E-BD79-969A1FB15CDB Q57909754-CFE63BBF-8BEA-44C3-A041-2529F11654A1

P2860

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.

http://www.wikidata.org/entity/Q37289632

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on October 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.

@en

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.

@nl

type

label

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.

@en

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.

@nl

prefLabel

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.

@en

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note.

@nl

P1433

Q37289632-2F2F64E5-7D13-41DF-BA15-1CC20440AE83

P1476

Q37289632-ACC03A99-FA8B-4FED-BA70-D4E0C272515F

P2093

Q37289632-0EFE9ACB-62D9-45A6-B8CD-EB55C15622E2

Q37289632-1CEFF140-38F0-4A9D-B5D9-899BCFA28A66

Q37289632-1E4F4744-2025-4BCA-B159-F9CAFB7F2A35

Q37289632-2C2DF77D-11A4-459C-A6EF-BB662C3214F9

Q37289632-7303862F-7F93-44E9-B1D1-E9D72A459E89

Q37289632-75EBAB5F-D32C-4D0B-980D-28D0800FF65E

Q37289632-9E0E6824-B400-45D5-802E-48F44E5D5B4D

Q37289632-F786CAE5-2C85-49CF-A509-5DDCA7A81DF9

P304

Q37289632-D9DA0918-03EC-4DD7-B5F0-B7331BD97B6F

P31

Q37289632-1CBB5266-A9B2-448D-B179-CBDF88324230

P356

Q37289632-FFF1249C-9C11-45B2-A3BC-5183764674DB

P407

Q37289632-FCA22688-D618-473B-B258-EC1DC079A1DF

P433

Q37289632-FC48EA34-E6F4-4234-A6FA-AFB9CF00A610

P478

Q37289632-CA30C3B9-5DB7-4283-AEEA-FC09D30C6CBE

P50

Q37289632-B608BEB1-4EC3-482A-99F6-9BA12462B453

P577

Q37289632-676E6FA4-5A7A-4F68-BFCA-CE65F2AE3FE8

P698

Q37289632-2C8BD5A7-97DD-40B1-B679-C44707EB5BB6

P356

P1433

P1476

alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note

@en

P2093

Bruce C Trapnell

http://www.w3.org/2001/XMLSchema#string

Edwin K Silverman

http://www.w3.org/2001/XMLSchema#string

Gerard Turino

http://www.w3.org/2001/XMLSchema#string

James K Stoller

http://www.w3.org/2001/XMLSchema#string

James Stocks

http://www.w3.org/2001/XMLSchema#string

Medical and Scientific Advisory Committee of the Alpha-1 Foundation

http://www.w3.org/2001/XMLSchema#string

Robert A Sandhaus

http://www.w3.org/2001/XMLSchema#string

Sarah E Everett

http://www.w3.org/2001/XMLSchema#string

P304

831-834

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1378/CHEST.08-0868

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

134

http://www.w3.org/2001/XMLSchema#string

P50

Charlie Strange

P577

2008-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18842915

http://www.w3.org/2001/XMLSchema#string